+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2019

  • ID: 4894151
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 280 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abhelix LLC
  • BlueWillow Biologics Inc
  • Gilead Sciences Inc
  • Johnson & Johnson
  • Pfizer Inc
  • Sigmovir Biosystems Inc
  • MORE
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2019, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 2, 43, 24 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 11 and 6 molecules, respectively.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abhelix LLC
  • BlueWillow Biologics Inc
  • Gilead Sciences Inc
  • Johnson & Johnson
  • Pfizer Inc
  • Sigmovir Biosystems Inc
  • MORE
Introduction
Respiratory Syncytial Virus (RSV) Infections - Overview
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Drug Profiles
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abhelix LLC, H2 2019
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2019
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2019 (Contd..2), H2 2019
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2019 (Contd..3), H2 2019
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2019 (Contd..4), H2 2019
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abhelix LLC
  • Abivax SA
  • ADMA Biologics Inc
  • Advac LLC
  • AlloVir Inc
  • Anima Biotech Inc
  • Aridis Pharmaceuticals Inc
  • Ark Biosciences Inc
  • Artificial Cell Technologies Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Beijing Advaccine Biotechnology Company Ltd
  • BioComo Inc
  • BlueWillow Biologics Inc
  • BravoVax Co Ltd
  • Calder Biosciences Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Cidara Therapeutics Inc
  • Clover Biopharmaceuticals
  • Codagenix Inc
  • Curevac AG
  • DBV Technologies SA
  • Enanta Pharmaceuticals Inc
  • Enyo Pharma SA
  • F. Hoffmann-La Roche Ltd
  • Gene Techno Science Co Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • HanaVax Inc
  • Humabs BioMed SA
  • iBio Inc
  • Icosavax Inc
  • IDBiologics Inc
  • ILiAD Biotechnologies LLC
  • Immunwork Inc
  • IMV Inc
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • mAbxience SA
  • Mapp Biopharmaceutical Inc
  • Meissa Vaccines Inc
  • Merck & Co Inc
  • Moderna Therapeutics Inc
  • Mucommune LLC
  • Navigen Inc
  • NeuClone Pty Ltd
  • Neuracle Science Co Ltd
  • Novavax Inc
  • Pfizer Inc
  • Phoenix Biotechnology Inc
  • Pneumagen Ltd
  • Profectus BioSciences Inc
  • ReViral Ltd
  • Riboscience LLC
  • Romark Laboratories LC
  • Sagimet Biosciences
  • Sanofi Pasteur SA
  • Shandong Danhong Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Sigmovir Biosystems Inc
  • TechnoVax Inc
  • Themis Bioscience GmbH
  • Vault Pharma Inc
  • Vaxart Inc
  • Viramatix Sdn Bhd
  • Viravaxx AG
  • Virometix AG
  • Visterra Inc
  • VLP Biotech Inc
  • Wyvern Pharmaceuticals Inc
  • X4 Pharmaceuticals Inc
  • Zhuhai Trinomab Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll